BioSpace News Archive

Sermonix Pharmaceuticals Inc., announced that a case report detailing a durable complete remission during its Phase 2 ELAINE-1 study was published in JCO Precision Oncology.

Today, Toragen Inc., a San Diego-based clinical-stage biotechnology company focused on developing uniquely selective drugs targeting cancers caused by viruses, announced positive safety data from Cohort 1 of its Phase 1 trial of TGN-S11, its first drug candidate, in patients with HPV-associated cancers.

A comprehensive new study from deCODE genetics, a subsidiary of Amgen, published today in Nature Genetics, provides insights into the epidemiology and somatic and germline genetics of clonal hematopoiesis.

Over the summer, the Quest for Health Equity team spearheaded a summer internship program, working with business leaders across the Quest Diagnostics organization to provide hands-on, real-work experience for scholars from the American Heart Association’s Historically Black Colleges and Universities and Hispanic Serving Institutions programs.

Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Lundbeck Pharmaceuticals LLC (Lundbeck) announce that treatment with REXULTI® (brexpiprazole) resulted in statistically significant and clinically meaningful improvements in adult patients with agitation associated with dementia due to Alzheimer’s disease, according to the complete results of the placebo-controlled pivotal phase 3 Study 213 (NCT03548584), published today in JAMA Neurology.

Kiora Pharmaceuticals (NASDAQ: KPRX) today announced topline results of a Phase I/II clinical trial demonstrating proof-of-concept that KIO-301, the company’s first-in-class small molecule, has the potential to meaningfully improve vision in patients with Retinitis Pigmentosa (RP) who are living with ultra-low vision or complete blindness.

Boehringer Ingelheim today announced promising 14-week Phase II data for BI 690517, a novel selective aldosterone synthase inhibitor (ASi).

Inventiva announced that the phase II trial led by Dr. Cusi in patients with type two diabetes has been accepted as late breaker, at the upcoming The Liver Meeting® 2023 hosted by the American Association for the Study of Liver Diseases on November 10-14, 2023 in Boston.

Apellis Pharmaceuticals, Inc. announced that the company approved the grant of equity awards to 20 new employees with a grant date of November 1, 2023, as equity inducement awards outside of the company’s 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.

QIAGEN announced the launch of the Microbiome WGS SeqSets, a comprehensive Sample to Insight workflow designed to provide an easy-to-use solution that maximizes efficiency and reproducibility in microbiome research.